# Daniel O'Connell

> Daniel O'Connell is a Series A investor at Arix Bioscience backing Biotechnology and Genetics. See 3 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [Arix Bioscience](https://shizune.co/investors/profile/arix-bioscience)
- Location: New York, United States
- Total investments: 3
- Last investment: Oct 2024
- Lead investor: 100%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/danielpoconnell/

Daniel O'Connell is a Series A investor at Arix Bioscience in New York focused on Biotechnology and Genetics. Daniel O'Connell, M.D., Ph.D., is an Associate on the Private Equity team. Before joining OrbiMed, Dr. O'Connell was the Associate Director of Cardiovascular Research at Arisaph Pharmaceuticals. In this role, he headed projects developing small molecules to raise HDL-cholesterol, culminating with an FDA filing of a novel compound in 2010.He has authored articles in peer-reviewed journals describing the design and synthesis of novel enzyme inhibitors and the effects of niacin in animal models of dyslipidemia. Dr. O'Connell received his MD and his PhD in biochemistry at Tufts University School of Medicine. He holds SB degrees from MIT in both chemistry and mathematics.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 2 | 67% |
| Genetics | 1 | 33% |
| Oncology | 1 | 33% |
| Health Care | 1 | 33% |

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 2 | 67% |
| Series B | 1 | 33% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Kivu Bioscience | Kivu Bioscience is a biotech company developing next-generation antibody-drug conjugates to deliver best-in-class therapeutics and focused on rapidly advancing next generation transformative assets. | $92M | Series A | Oct 28, 2024 |  |
| LogicBio Therapeutics | LogicBio develops gene therapy vectors for previously incurable genetic and infectious diseases, including: hemophilia, HIV/AIDS and methylmalonic acidemia (MMA). Our proprietary technology based on the non-pathogenic Adeno-Associated Viral (AAV) vector offers superior efficiency and safety compared to all competitors on the market, and isuniquely suited for the treatment of children as well as adults. | $45M | Series B | Jun 29, 2017 |  |
| LogicBio Therapeutics | LogicBio develops gene therapy vectors for previously incurable genetic and infectious diseases, including: hemophilia, HIV/AIDS and methylmalonic acidemia (MMA). Our proprietary technology based on the non-pathogenic Adeno-Associated Viral (AAV) vector offers superior efficiency and safety compared to all competitors on the market, and isuniquely suited for the treatment of children as well as adults. | $4M | Series A |  |  |

3 of 3 investments shown.

## Co-investors
- [Arix Bioscience](https://shizune.co/investors/profile/arix-bioscience) — VC Fund, 1 deal together
- [Biodiscovery V](https://shizune.co/investors/profile/biodiscovery-v) — VC Fund, 1 deal together
- [BioGeneration Ventures](https://shizune.co/investors/profile/biogeneration-ventures) — VC Fund, 1 deal together
- [BOM](https://shizune.co/investors/profile/brabantse-ontwikkelings-maatschappij-bom) — VC Fund, 1 deal together
- [Andera Partners](https://shizune.co/investors/profile/edmond-de-rothschild-investment-partners) — VC Fund, 1 deal together
- [Gimv](https://shizune.co/investors/profile/gimv) — VC Fund, 1 deal together

## About Arix Bioscience

VC Fund · London, United Kingdom

Arix Bioscience is a global healthcare and life science company that drives value in private and public companies through operational and strategic direction as well as patient capital Their extensive experience in academic science, clinical and commercial strategy, company operations, mergers and acquisitions, venture capital and corporate financeputs them in an especially strong position to build and support a wide range of businesses and technologies.Arix Bioscience has privileged agreements with leading universities in the UK, Europe and Australia, providing direct access to innovative new technologies. They also have access to a broad range of research projects from US academic institutions.

5 contacts available at Arix Bioscience.

| Name | Title | Profile |
| --- | --- | --- |
| Daniel O'Connell | Investment Manager | https://shizune.co/investors/profile/daniel-oconnell |
| James Rawlingson | Chief Financial Officer | https://shizune.co/investors/profile/james-rawlingson |
| Jonathan Tobin | Managing Director | https://shizune.co/investors/profile/jonathan-tobin |
| Chris Evans | Deputy Chairman | https://shizune.co/investors/profile/chris-evans-9 |
| Chris Evans | Deputy Chairman | https://shizune.co/investors/profile/chris-evans-3 |

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## FAQ

### What does Daniel O'Connell invest in?

Daniel O'Connell invests primarily in Biotechnology, Genetics and Oncology startups, most often at Series A and Series B stage. Most of the 3 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Daniel O'Connell last invest?

The most recent investment recorded for Daniel O'Connell closed in Oct 2024. Shizune tracks 3 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co